MedElevator Войти в исследования
← Поиск публикаций
Медицинская библиотека · American health & drug benefits · 2009

Estimates of commercial population at high risk for cardiovascular events: impact of aggressive cholesterol reduction.

Fitch Kathryn, Goldberg Sara W, Iwasaki Kosuke, Pyenson Bruce S, Kuznik Andreas, Solomon Henry A

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

To model the financial and health outcomes impact of intensive statin therapy compared with usual care in a high-risk working-age population (actively employed, commercially insured health plan members and their adult dependents). The target population consists of working-age people who are considered high-risk for cardiovascular disease events because of a history of coronary heart disease.

STUDY

DESIGN

Three-year event forecast for a sample population generated from the National Health and Nutrition Examination Survey data.

METHODS

Using Framingham risk scoring system, the probability of myocardial infarction or stroke events was calculated for a representative sample population, ages 35 to 69 years, of people at high risk for cardiovascular disease, with a history of coronary heart disease. The probability of events for each individual was used to project the number of events expected to be generated for this population. Reductions in cardiovascular and stroke events reported in clinical trials with aggressive statin therapy were applied to these cohorts. We used medical claims data to model the cohorts' event costs. All results are adjusted to reflect the demographics of a typical working-age population.

RESULTS

The high-risk cohort (those with coronary heart disease) comprises 4% of the 35- to 69-year-old commercially insured population but generates 22% of the risk for coronary heart disease and stroke. Reduced event rates associated with intensive statin therapy yielded a $58 mean medical cost reduction per treated person per month; a typical payer cost for a 30-day supply of intensive statin therapy is approximately $57.

CONCLUSIONS

Aggressive low-density lipoprotein cholesterol-lowering therapy for working-age people at high risk for cardiovascular events and with a history of heart disease appears to have a significant potential to reduce the rate of clinical events and is cost-neutral for payers.

Для цитирования: Fitch Kathryn, Goldberg Sara W, Iwasaki Kosuke, Pyenson Bruce S, Kuznik Andreas, Solomon Henry A. Estimates of commercial population at high risk for cardiovascular events: impact of aggressive cholesterol reduction.. American health & drug benefits. 2009.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.